Try Calculator
← Back to Compound Library GH SECRETAGOGUES

CJC-1295 + Ipamorelin Blend

CJC-1295 (no DAC) + Ipamorelin is a peptide combination that acts through complementary mechanisms to stimulate endogenous growth hormone (GH) secretion. This combination represents a widely researched approach to enhancing pulsatile GH release while preserving physiological feedback mechanisms. CJC-1295 (no DAC), also known as Modified GRF (1-29) or sermorelin analog, is a growth hormone-releasing hormone (GHRH) analog with modifications that extend its half-life beyond native GHRH while maintaining pulsatile release patterns. Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R1a) agonist, functioning as a ghrelin mimetic with minimal effects on cortisol, prolactin, or acetylcholine. The synergistic combination exploits two distinct pathways of GH regulation, potentially producing amplified pulsatile GH release compared to either compound alone. Important: Neither CJC-1295 nor Ipamorelin is FDA-approved for medical use. Both are classified as research chemicals. Competitive athletes should note that both compounds are prohibited by the World Anti-Doping Agency (WADA) at all times.

Why These Peptides Are Paired

The rationale for combining CJC-1295 (no DAC) and Ipamorelin lies in their complementary mechanisms of action:

GH through activation of GHRH receptors. Its modifications include substitution of four amino acids in the native GHRH sequence, enhancing stability against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4).

activates GHS-R1a receptors without significant agonism of other ghrelin-related pathways. Unlike earlier growth hormone secretagogues (GHRP-2, GHRP-6), ipamorelin demonstrates minimal elevation of ACTH, cortisol, or prolactin even at supraphysiological doses.

When administered concurrently, these peptides activate both the GHRH pathway and the ghrelin receptor pathway, potentially producing synergistic GH release that mimics youthful secretion patterns more closely than single-pathway stimulation.

The Importance of “No DAC”

The designation “no DAC” refers to the absence of Drug Affinity Complex modification. DAC is a chemical moiety that binds to serum albumin, dramatically extending the half-life of peptides to approximately 6-8 days. CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes, similar to native GHRH but with enhanced stability against DPP-4 degradation. This shorter half-life offers several theoretical advantages:

primarily during deep sleep. Short-acting GHRH analogs support this physiological pattern rather than creating sustained elevation.

receptor downregulation. Pulsatile stimulation may better preserve receptor sensitivity over extended protocols.

natural GH secretion patterns (primarily nocturnal).

protocol design for specific research objectives.

Mechanism of Action

CJC-1295 (no DAC) – GHRH Pathway Activation

The hypothalamus naturally secretes GHRH in a pulsatile manner, stimulating somatotroph cells in the anterior pituitary to release GH. Native GHRH (GHRH 1-44) has a plasma half-life of approximately 7 minutes due to rapid cleavage by DPP-4 at the N-terminal Tyr¹-Ala² bond. CJC-1295 (no DAC) incorporates four amino acid substitutions in the GHRH sequence that confer resistance to DPP-4 degradation while preserving receptor binding affinity. The key modifications include:

These modifications extend the functional half-life to approximately 30 minutes while maintaining the rapid onset and pulsatile nature of GH release. Upon binding to GHRH receptors (GHRHR) on pituitary somatotrophs, CJC-1295 (no DAC) activates adenylyl cyclase, increasing intracellular cAMP and triggering GH secretion. Clinical data from Teichman et al. (2006) demonstrated that a single subcutaneous injection of CJC-1295 (with DAC, different formulation) increased mean GH concentrations 2- to 10-fold above baseline, with effects persisting for 6+ days. The no-DAC version exhibits briefer but more physiologically patterned effects.

Ipamorelin – Ghrelin Receptor Pathway Activation

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide that selectively binds to and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), also known as the ghrelin receptor. Endogenous ghrelin is an orexigenic hormone that also potently stimulates GH release. The selectivity of ipamorelin is its defining characteristic. Raun et al. (1998) demonstrated that ipamorelin induced dose-dependent GH release without significantly affecting plasma concentrations of ACTH, cortisol, or prolactin—even at doses exceeding 200 times the ED50 for GH stimulation. This contrasts sharply with earlier GH secretagogues:

significantly.

prolactin, albeit to a lesser degree.

recognition as the first truly selective GH secretagogue. Pharmacokinetic studies by Gobburu et al. (1999) established that ipamorelin has a plasma half- life of approximately 2 hours, with peak GH concentrations occurring approximately 40 minutes (0.67 hours) post-injection. The GH pulse follows a rapid exponential rise and decline, returning to baseline levels within several hours.

The Combined Effect

When CJC-1295 (no DAC) and ipamorelin are administered together, they activate complementary pathways:

cascade This dual-pathway stimulation may produce synergistic GH release. While direct human studies of the combination are limited, the mechanistic basis and anecdotal evidence from research contexts suggest GH output 3- to 5-fold greater than single-agent use. Critically, this combination preserves endogenous negative feedback mechanisms. Unlike exogenous GH administration, which suppresses hypothalamic GHRH and pituitary somatotroph function through IGF-1-mediated negative feedback, secretagogue combinations work through the body’s own regulatory systems. The hypothalamus and pituitary remain functional and responsive, maintaining physiological control over GH secretion patterns.

Research-Supported Effects

Increased Growth Hormone Production

The primary documented effect is enhanced GH secretion. Teichman et al. (2006) reported that CJC-1295 (with DAC) increased mean plasma GH concentrations 2- to 10-fold, with effects lasting 6+ days after a single injection. IGF-1 levels increased 1.5- to 3-fold above baseline and remained elevated for 9-11 days. For the no-DAC version, the GH elevation is more pulsatile and shorter-lived, requiring more frequent administration to maintain elevated mean GH levels. Ipamorelin studies show dose- dependent GH release with peak concentrations at approximately 40 minutes post-injection.

Potential Effects on Muscle Growth and Recovery

Growth hormone’s anabolic effects are mediated primarily through IGF-1, which is produced in response to GH stimulation (primarily hepatic synthesis, though local tissue production also occurs). IGF-1 promotes:

While the theoretical basis for enhanced muscle protein synthesis is sound, direct controlled trials demonstrating muscle hypertrophy from CJC-1295/Ipamorelin are limited. Anecdotal reports suggest improved recovery between training sessions and enhanced lean mass accrual, particularly when combined with resistance training and adequate protein intake.

Fat Loss

GH exhibits lipolytic effects through several mechanisms:

adipocytes

Some clinical practices report fat loss outcomes with GH secretagogue protocols. However, these reports lack the rigor of controlled trials and often involve concurrent interventions (dietary modifications, exercise programs) that confound attribution. The claim of “12 pounds of fat loss over six weeks, with 4 pounds being visceral fat” cited in some sources lacks peer-reviewed validation and should be considered preliminary or anecdotal.

Sleep Quality

Endogenous GH secretion is tightly coupled to slow-wave sleep (SWS), with the majority of daily GH output occurring during the first few hours of nocturnal sleep. Enhancement of GH secretion may improve sleep architecture through bidirectional mechanisms:

Anecdotal reports frequently mention improved sleep quality, faster sleep onset, and more refreshing sleep. However, objective polysomnographic data from controlled trials of this combination are not currently available.

Skin and Connective Tissue

GH and IGF-1 stimulate fibroblast proliferation and collagen synthesis. Potential effects include:

These effects, if present, typically manifest over extended timeframes (8-12+ weeks) and are generally subtle. Clinical validation through controlled trials is limited.

Cognitive Function

GH receptors are expressed throughout the central nervous system, particularly in the hippocampus, cortex, and hypothalamus. GH and IGF-1 have documented roles in:

Some users report subjective improvements in mental clarity, focus, and mood stability. However, the evidence base for cognitive enhancement with GH secretagogues remains largely anecdotal. Controlled neurocognitive testing data are not currently available for this combination.

Key Clinical Studies

CJC-1295 Human Study (Teichman et al., 2006)

Publication: Journal of Clinical Endocrinology & Metabolism

Study Design: Two randomized, placebo-controlled, double-blind trials in healthy adults aged 21-61 Key Findings:

Important Note: This study used CJC-1295 with DAC, which has markedly different pharmacokinetics than the no-DAC version discussed in this document. The no-DAC version has a substantially shorter duration of action.

Ipamorelin Pharmacokinetics (Gobburu et al., 1999)

Publication: Pharmaceutical Research

Study Design: Dose-escalation trial in 40 healthy male volunteers Key Findings:

Ipamorelin Selectivity Study (Raun et al., 1998)

Publication: European Journal of Endocrinology

Key Finding: Ipamorelin did not significantly increase ACTH or cortisol at any dose tested, including doses exceeding 200 times the effective dose for GH stimulation. This established ipamorelin as the first highly selective GH secretagogue, with minimal effects on stress hormones—a major advantage over GHRP-2 and GHRP-6.

CJC-1295 Pulsatility Study (Ionescu & Frohman, 2006)

Publication: Journal of Clinical Endocrinology & Metabolism

Key Finding: CJC-1295 preserved the natural pulsatile pattern of GH secretion even during continuous stimulation, demonstrating that GHRH analog administration does not necessarily eliminate physiological secretion dynamics.

Dosing Protocol

The most commonly referenced protocol involves daily subcutaneous injections, typically administered before bedtime to align with the natural nocturnal GH surge during slow-wave sleep.

Standard Protocol

potential receptor desensitization

Dosing by Body Weight

Split Dosing Protocol (Advanced) Some protocols employ twice-daily administration to generate multiple GH pulses:

Morning administration should occur in a fasted state to avoid glucose-induced insulin elevation, which can blunt GH response through inhibitory effects on somatotroph function.

Important Dosing Considerations

intake. Elevated glucose and insulin suppress GH secretion through multiple mechanisms, including direct inhibition of somatotroph activity and potentiation of somatostatin release.

GH secretagogue studies. Tesamorelin (a GHRH analog) trials used daily dosing for 26 weeks. MK-677 (an oral GHS-R1a agonist) studies employed daily dosing for up to two years with sustained GH and IGF-1 elevation. Acute receptor desensitization (tachyphylaxis) resolves within approximately 60 minutes between doses. Chronic desensitization may develop around 16 weeks, which is the rationale for the 4-week off- cycle.

communities but lacks scientific rationale. It does not address acute desensitization (which resolves in ~60 minutes) nor does it prevent chronic desensitization (which requires 4+ weeks off). This pattern appears to be a compromise without clear mechanistic benefit.

assess tolerance. Gradually increase based on subjective response and side effect profile. Higher doses do not necessarily produce proportionally greater benefits and may increase risk of side effects (e.g., water retention, hypoglycemia risk).

Reconstitution and Preparation

Most CJC-1295/Ipamorelin blends are provided as lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water before use.

Materials Required

Reconstitution Procedure

swabs. Allow to air dry.

final concentration; see calculations below).

never inject directly onto the lyophilized powder, as this can denature the peptides.

do not shake) until the powder is fully dissolved. This typically takes 2-5 minutes.

visible particles, do not use.

Concentration Calculations

Most pre-mixed blends contain 5 mg CJC-1295 (no DAC) + 5 mg Ipamorelin = 10 mg total peptide per vial. Using 2 mL reconstitution volume:

Using 3 mL reconstitution volume:

Note: The 3 mL dilution provides easier measurement for smaller doses and reduces measurement error with standard insulin syringes.

Administration Technique

Subcutaneous injection is the standard route of administration for this peptide combination.

Injection Procedure

between sites

Preferred Injection Sites

Storage and Handling

Before Reconstitution

After Reconstitution

efficacy)

Side Effects and Adverse Reactions

The CJC-1295 (no DAC)/Ipamorelin combination generally exhibits a favorable side effect profile compared to exogenous GH administration or earlier GH secretagogues. Most reported effects are mild and transient. Common Side Effects (typically resolve within 1-2 weeks)

Less Common Side Effects

Symptoms Requiring Dose Reduction or Discontinuation

Important Distinction from Other GH Secretagogues

Unlike GHRP-2 and GHRP-6, which significantly elevate cortisol and prolactin, ipamorelin demonstrates selectivity for GH release. The increased appetite associated with ipamorelin is generally milder than that caused by GHRP-6 and may be beneficial for individuals seeking to increase caloric intake for muscle gain.

Contraindications and Precautions

Absolute Contraindications (Do Not Use)

tumor growth in individuals with active cancer.

unless cleared by an oncologist, as elevated GH/IGF-1 may increase recurrence risk.

mediated neovascularization.

insulin sensitivity, potentially worsening glycemic control. Relative Contraindications (Use with Caution)

insulin resistance through multiple mechanisms.

symptoms.

individuals should monitor blood pressure.

requirements and side effect risk.

Drug Interactions

of diabetes medications to maintain glycemic control.

secretion and reduce effectiveness of GH secretagogues.

may blunt GH response.

Optimization Strategies

Timing Considerations

Administer 2-3 hours after the last meal, ideally before bedtime. The fasting state is critical— elevated glucose and insulin suppress GH secretion through:

Bedtime administration aligns with the natural circadian pattern of GH secretion, which peaks during slow-wave sleep in the first few hours after sleep onset.

Consistency

GH secretagogues exert cumulative effects on IGF-1 levels and tissue remodeling. Consistent daily administration for a minimum of 8-12 weeks is necessary to observe meaningful changes in body composition, recovery, or other parameters.

Sleep Optimization

The majority of endogenous GH secretion occurs during slow-wave sleep. The peptides enhance this process, but adequate sleep is required to realize the benefit. Aim for 7-9 hours of quality sleep per night. Sleep deprivation or fragmented sleep will blunt GH output regardless of secretagogue use.

Resistance Training

GH and IGF-1 promote protein synthesis, but a mechanical stimulus is required to direct this anabolic effect toward muscle tissue. Progressive resistance training 3-5 times per week provides the necessary stimulus. Without training, elevated GH/IGF-1 will primarily affect general metabolism and tissue turnover rather than muscle hypertrophy.

Protein Intake

Enhanced protein synthesis capacity requires adequate substrate. Target 0.8-1.0 grams of protein per pound of body weight daily (1.8-2.2 g/kg). Distribution throughout the day with particular attention to post-training intake may optimize muscle protein accretion.

Progress Tracking

Body composition changes occur gradually. Track multiple metrics:

Legal and Regulatory Status

United States

Neither CJC-1295 nor Ipamorelin is approved by the US Food and Drug Administration for any medical indication. Both are classified as research chemicals. The sale of these compounds “for human consumption” or with claims of therapeutic benefit may violate federal law. WADA Status (Athletic Competition) Both CJC-1295 and Ipamorelin are prohibited at all times (in-competition and out-of- competition) under the World Anti-Doping Agency Prohibited List:

Hormones, Growth Factors, Related Substances, and Mimetics)

Warning for Competitive Athletes: Use of these compounds will result in a positive drug test and potential sanctions. Do not use if subject to WADA-compliant testing in any sport.

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC? The DAC (Drug Affinity Complex) modification extends the half-life to 6-8 days through albumin binding, creating sustained GH elevation. The no-DAC version (Modified GRF 1-29) has a half-life of approximately 30 minutes, producing pulsatile GH release that more closely mimics natural physiology. Most combination protocols use the no-DAC version to preserve physiological secretion patterns. How long until results are noticeable? Subjective improvements in sleep quality and recovery may occur within 1-2 weeks. Measurable changes in body composition (muscle mass, fat distribution) typically become apparent after 6-8 weeks of consistent use. Full effects on tissue remodeling and metabolic parameters develop over 3-6 months. Can this combination be stacked with other peptides? Yes. Common additions include:

this increases appetite and water retention risk Stacking multiple compounds increases complexity and side effect risk. Start with the CJC- 1295/Ipamorelin combination alone before adding additional agents. Why is bedtime administration recommended? Endogenous GH secretion peaks during slow-wave sleep, particularly in the first few hours after sleep onset. Administering GH secretagogues before bed amplifies this natural surge and leverages the body’s existing circadian rhythm. Additionally, the fasting state at bedtime (assuming no late-night eating) optimizes GH response. Will this suppress natural GH production? Unlike exogenous recombinant GH, which suppresses endogenous GH production through negative feedback (elevated IGF-1 inhibits hypothalamic GHRH and pituitary GH secretion), GH secretagogues work through the body’s own regulatory pathways. They stimulate the pituitary to produce more GH rather than replacing it. Current evidence suggests pituitary function remains intact with secretagogue use, though temporary receptor desensitization may occur with prolonged continuous use (hence the recommendation for 4-week off-cycles after 12- 16 weeks). Is increased appetite a major side effect? Ipamorelin’s activation of ghrelin receptors can increase appetite, but the effect is generally milder than that of GHRP-6. Most individuals find the hunger increase manageable. For those seeking to increase caloric intake for muscle gain, this may actually be beneficial. What happens when use is discontinued? GH and IGF-1 levels return to baseline relatively quickly after discontinuation. There is no acute withdrawal syndrome. However, the adaptive changes in body composition (increased muscle mass, reduced fat mass) will gradually diminish without continued use or maintenance of the training and nutritional stimulus that supported them.

References

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416.

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. Alba M, Fintini D, Bowers CY, Salvatori R. Effects of long-term treatment with CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, in normal mice. Growth Horm IGF Res. 2005;15(5):335-343. Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-41. World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List 2024. https://www.wada-ama.org/en/prohibited-list

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch